Portage Biotech Corp (PRTG) Price to Earnings Ratio

Portage Biotech Inc. is currently implementing strict cost-cutting measures and suspending early-stage trials to preserve liquidity. Since biopharmaceutical success depends on regulatory approvals rather than economics, this price action chart on GURU.Markets reflects a value of -0.10. The development of anti-tumor agents is based on partnerships with oncology centers to create synergistic treatment methods.

Portage (PRTG) - Price to Earnings Ratio from 07/04/2022 to 09/04/2025

Comprehensive metric breakdowns and analytics for Portage (PRTG)

- price and consensus price forecast:

Stock Price portagebiotech.com|PRTG - Price Target Chart

- market capitalization details:

Market Value Portage Biotech Inc.|PRTG - Real Price to Acquire Entire Company

- book capitalization information:

Accounting Value of a Share Portage Biotech|PRTG - Company Book Value|Market-to-Book Ratio portagebiotech.com|PRTG - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples indicators:

PRTG - Net Profit|Projected Net Profit Portage Biotech Inc.|PRTG - Price to Earnings Ratio|Projected Price to Earnings Ratio Portage Biotech Inc|PRTG - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Portage Biotech Inc.|PRTG - Operating profit before deduction of amortization|Earnings per share for the last four quarters Portage Biotech|PRTG - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months portagebiotech.com|PRTG - Earnings growth in current year|Expected net earnings per share growth next year Portage Biotech Inc.

Comprehensive company analysis:PRTG (portagebiotech.com)

Portage Biotech Inc. (PRTG) has effectively ceased the development of anti-tumor drugs due to a critical capital shortage. The P/E ratio reflects the cost of a single unit of profit, measuring the investment payback period via net income. An increase in this coefficient signals inflated market expectations amid business stagnation. It is essential for investors to benchmark this metric against industry leaders. The relative P/E valuation of the company on this chart confirms the issuer's loss of competitiveness.

Analysis of competing companies